Decay characteristics of HIV-1-infected compartments during combination therapy View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

1997-05

AUTHORS

Alan S. Perelson, Paulina Essunger, Yunzhen Cao, Mika Vesanen, Arlene Hurley, Kalle Saksela, Martin Markowitz, David D. Ho

ABSTRACT

Analysis of changes in viral load after initiation of treatment with potent antiretroviral agents has provided substantial insight into the dynamics of human immunodeficiency virus type 1 (HIV-1)1–3. The concentration of HIV-1 in plasma drops by ∼99% in the first two weeks of treatment owing to the rapid elimination of free virus with a half-life (t1/2) of ≤6 hours and loss of productively infected cells with a t1/2 of 1.6 days3. Here we show that with combination therapy this initial decrease is followed by a slower second-phase decay of plasma viraemia. Detailed mathematical analysis shows that the loss of long-lived infected cells (t1/2of1–4weeks) is a major contributor to the second phase, whereas the activation of latently infected lymphocytes (t1/2 of 0.5–2 weeks) is only a minor source. Based on these decay characteristics, we estimate that 2.3–3.1 years of a completely inhibitory treatment would be required to eliminate HIV-1 from these compartments. To eradicate HIV-1 completely, even longer treatment may be needed because of the possible existence of undetected viral compartments or sanctuary sites. More... »

PAGES

188-191

Journal

TITLE

Nature

ISSUE

6629

VOLUME

387

Related Patents

  • Measurement Of Biosynthesis And Breakdown Rates Of Biological Molecules That Are Inaccessible Or Not Easily Accessible To Direct Sampling, Non-Invasively, By Label Incorporation Into Metabolic Derivatives And Catabolitic Products
  • Methods For Measuring Rates Of Reverse Cholesterol Transport In Vivo, As An Index Of Anti-Atherogenesis
  • Methods For Measuring Cellular Proliferation And Destruction Rates In Vitro And In Vivo
  • Molecular Flux Rates Through Critical Pathways Measured By Stable Isotope Labeling In Vivo, As Biomarkers Of Drug Action And Disease Activity
  • Administering Isotope Labeled Water To Tissue; Measurement; Calibration
  • Primers, Probes And Methods For Sensitive, Specific Detection And Monitoring Of Hiv-1 And Hcv
  • Measurement Of Cell Prolferation Or Cell Destruction; Obtain Cells, Incubate With Labeled Nucleotides Sequences, Detect Labeled Nucleotides In Cells
  • Methods Of Treating Hiv And Aids And The Elimination Of Latent Reservoirs Of Hiv Infection Using Selectin, Galectin, And Siglec Antagonists
  • Metabolic Flux Measurement, Imaging And Microscopy
  • Molecular Flux Rates Through Critical Pathways Measured By Stable Isotope Labeling In Vivo, As Biomarkers Of Drug Action And Disease Activity
  • Method For Replacing Biomarkers Of Protein Kinetics From Tissue Samples By Biomarkers Of Protein Kinetics From Body Fluids After Isotopic Labeling In Vivo
  • Expression Of Hiv Polypeptides And Production Of Virus-Like Particles
  • Molecular Flux Rates Through Critical Pathways Measured By Stable Isotope Labeling In Vivo, As Biomarkers Of Drug Action And Disease Activity
  • Methods For Measuring Rates Of Reserve Cholesterol Transport In Vivo, As An Index Of Anti-Atherogenesis
  • Assay For Detecting Human Immunodeficiency Virus (Hiv)
  • Measuring Isotope Labelled Dna Synthesis And Destruction; Cancer Diagnosis; Prognosing Human Immunodeficiency Virus
  • Molecular Flux Rates Through Critical Pathways Measured By Stable Isotope Labeling In Vivo, As Biomarkers Of Drug Action And Disease Activity
  • Molecular Flux Rates Through Critical Pathways Measured By Stable Isotope Labeling In Vivo, As Biomarkers Of Drug Action And Disease Activity
  • Methods Of Monitoring Treatment Effectiveness In Hiv-Infected Patients Receiveing Intensified Haart Regimens By Measuring Episomal 2-Ltr Circles
  • Monitoring Two Dimensions Of Diabetes Pathogenesis
  • Method For Automated, Large-Scale Measurement Of The Molecular Flux Rates Of The Proteome Or The Organeome Using Mass Spectrometry
  • Method For Automated, Large-Scale Measurement Of The Molecular Flux Rates Of The Proteome Or The Organeome Using Mass Spectrometry
  • Method For Automated, Large-Scale Measurement Of The Molecular Flux Rates Of The Proteome Or The Organeome Using Mass Spectrometry
  • Methods For Determining Total Body Skeletal Muscle Mass
  • Compositions And Methods Related To Characterizing Proviral Reservoirs
  • Method For High-Throughput Screening Of Compounds And Combinations Of Compounds For Discovery And Quantification Of Actions, Particularly Unanticipated Therapeutic Or Toxic Actions, In Biological Systems
  • Methods For Identifying The Effect Of A Drug Agent On The Metabolism Of Sugars And Fats In An Individual
  • Measurement Of Biosynthesis And Breakdown Rates Of Biological Molecules That Are Inaccessible Or Not Easily Accessible To Direct Sampling, Non-Invasively, By Label Incorporation Into Metabolic Derivatives And Catabolic Products
  • Molecular Flux Rates Through Critical Pathways Measured By Stable Isotope Labeling In Vivo, As Biomarkers Of Drug Action And Disease Activity
  • Molecular Flux Rates Through Critical Pathways Measured By Stable Isotope Labeling In Vivo, As Biomarkers Of Drug Action And Disease Activity
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.1038/387188a0

    DOI

    http://dx.doi.org/10.1038/387188a0

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1026180202

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/9144290


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical and Health Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1108", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical Microbiology", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Anti-HIV Agents", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "CD4-Positive T-Lymphocytes", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Drug Therapy, Combination", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "HIV Infections", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "HIV Protease Inhibitors", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "HIV-1", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Half-Life", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Humans", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Isoquinolines", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Lamivudine", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Leukocytes, Mononuclear", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Macrophages", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Mathematics", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Models, Biological", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Nelfinavir", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Proviruses", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "RNA, Viral", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Reverse Transcriptase Inhibitors", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Sulfonic Acids", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Viral Load", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Viremia", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Virus Latency", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Zidovudine", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "alternateName": "Theoretical Division, Los Alamos National Laboratory, 87545, Los Alamos, New Mexico, USA", 
              "id": "http://www.grid.ac/institutes/grid.148313.c", 
              "name": [
                "Theoretical Division, Los Alamos National Laboratory, 87545, Los Alamos, New Mexico, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Perelson", 
            "givenName": "Alan S.", 
            "id": "sg:person.01335541022.50", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01335541022.50"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Theoretical Division, Los Alamos National Laboratory, 87545, Los Alamos, New Mexico, USA", 
              "id": "http://www.grid.ac/institutes/grid.148313.c", 
              "name": [
                "Theoretical Division, Los Alamos National Laboratory, 87545, Los Alamos, New Mexico, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Essunger", 
            "givenName": "Paulina", 
            "id": "sg:person.01342367032.44", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01342367032.44"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Theoretical Division, Los Alamos National Laboratory, 87545, Los Alamos, New Mexico, USA", 
              "id": "http://www.grid.ac/institutes/grid.148313.c", 
              "name": [
                "Theoretical Division, Los Alamos National Laboratory, 87545, Los Alamos, New Mexico, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Cao", 
            "givenName": "Yunzhen", 
            "id": "sg:person.01343017451.31", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01343017451.31"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Theoretical Division, Los Alamos National Laboratory, 87545, Los Alamos, New Mexico, USA", 
              "id": "http://www.grid.ac/institutes/grid.148313.c", 
              "name": [
                "Theoretical Division, Los Alamos National Laboratory, 87545, Los Alamos, New Mexico, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Vesanen", 
            "givenName": "Mika", 
            "id": "sg:person.01370270152.62", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01370270152.62"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Theoretical Division, Los Alamos National Laboratory, 87545, Los Alamos, New Mexico, USA", 
              "id": "http://www.grid.ac/institutes/grid.148313.c", 
              "name": [
                "Theoretical Division, Los Alamos National Laboratory, 87545, Los Alamos, New Mexico, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Hurley", 
            "givenName": "Arlene", 
            "id": "sg:person.01154520206.45", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01154520206.45"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Theoretical Division, Los Alamos National Laboratory, 87545, Los Alamos, New Mexico, USA", 
              "id": "http://www.grid.ac/institutes/grid.148313.c", 
              "name": [
                "Theoretical Division, Los Alamos National Laboratory, 87545, Los Alamos, New Mexico, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Saksela", 
            "givenName": "Kalle", 
            "id": "sg:person.01172560566.03", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01172560566.03"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Theoretical Division, Los Alamos National Laboratory, 87545, Los Alamos, New Mexico, USA", 
              "id": "http://www.grid.ac/institutes/grid.148313.c", 
              "name": [
                "Theoretical Division, Los Alamos National Laboratory, 87545, Los Alamos, New Mexico, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Markowitz", 
            "givenName": "Martin", 
            "id": "sg:person.016673513377.34", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016673513377.34"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Theoretical Division, Los Alamos National Laboratory, 87545, Los Alamos, New Mexico, USA", 
              "id": "http://www.grid.ac/institutes/grid.148313.c", 
              "name": [
                "Theoretical Division, Los Alamos National Laboratory, 87545, Los Alamos, New Mexico, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Ho", 
            "givenName": "David D.", 
            "id": "sg:person.01342202624.34", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01342202624.34"
            ], 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "sg:pub.10.1038/360264a0", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1017658165", 
              "https://doi.org/10.1038/360264a0"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/373123a0", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1014949926", 
              "https://doi.org/10.1038/373123a0"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nm1295-1284", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1020288435", 
              "https://doi.org/10.1038/nm1295-1284"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/387183a0", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1036513917", 
              "https://doi.org/10.1038/387183a0"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/bf01468720", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1005527589", 
              "https://doi.org/10.1007/bf01468720"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/377740a0", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1020157720", 
              "https://doi.org/10.1038/377740a0"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "1997-05", 
        "datePublishedReg": "1997-05-01", 
        "description": "Analysis of changes in viral load after initiation of treatment with potent antiretroviral agents has provided substantial insight into the dynamics of human immunodeficiency virus type 1 (HIV-1)1\u20133. The concentration of HIV-1 in plasma drops by \u223c99% in the first two weeks of treatment owing to the rapid elimination of free virus with a half-life (t1/2) of \u22646 hours and loss of productively infected cells with a t1/2 of 1.6 days3. Here we show that with combination therapy this initial decrease is followed by a slower second-phase decay of plasma viraemia. Detailed mathematical analysis shows that the loss of long-lived infected cells (t1/2of1\u20134weeks) is a major contributor to the second phase, whereas the activation of latently infected lymphocytes (t1/2 of 0.5\u20132 weeks) is only a minor source. Based on these decay characteristics, we estimate that 2.3\u20133.1 years of a completely inhibitory treatment would be required to eliminate HIV-1 from these compartments. To eradicate HIV-1 completely, even longer treatment may be needed because of the possible existence of undetected viral compartments or sanctuary sites.", 
        "genre": "article", 
        "id": "sg:pub.10.1038/387188a0", 
        "isAccessibleForFree": false, 
        "isPartOf": [
          {
            "id": "sg:journal.1018957", 
            "issn": [
              "0028-0836", 
              "1476-4687"
            ], 
            "name": "Nature", 
            "publisher": "Springer Nature", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "6629", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "387"
          }
        ], 
        "keywords": [
          "HIV-1", 
          "combination therapy", 
          "human immunodeficiency virus type 1", 
          "immunodeficiency virus type 1", 
          "initiation of treatment", 
          "weeks of treatment", 
          "potent antiretroviral agents", 
          "second-phase decay", 
          "virus type 1", 
          "plasma viraemia", 
          "viral load", 
          "antiretroviral agents", 
          "sanctuary site", 
          "type 1", 
          "free virus", 
          "longer treatment", 
          "rapid elimination", 
          "infected cells", 
          "viral compartments", 
          "inhibitory treatment", 
          "treatment", 
          "therapy", 
          "initial decrease", 
          "days3", 
          "cells", 
          "viraemia", 
          "compartments", 
          "HIV", 
          "major contributor", 
          "lymphocytes", 
          "weeks", 
          "virus", 
          "t1/2", 
          "activation", 
          "hours", 
          "loss", 
          "analysis of changes", 
          "initiation", 
          "agents", 
          "years", 
          "substantial insight", 
          "decrease", 
          "elimination", 
          "possible existence", 
          "analysis", 
          "contributor", 
          "second phase", 
          "changes", 
          "concentration", 
          "characteristics", 
          "sites", 
          "plasma drop", 
          "minor source", 
          "insights", 
          "drop", 
          "phase", 
          "load", 
          "source", 
          "existence", 
          "decay characteristics", 
          "decay", 
          "dynamics", 
          "mathematical analysis", 
          "detailed mathematical analysis"
        ], 
        "name": "Decay characteristics of HIV-1-infected compartments during combination therapy", 
        "pagination": "188-191", 
        "productId": [
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1026180202"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.1038/387188a0"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "9144290"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.1038/387188a0", 
          "https://app.dimensions.ai/details/publication/pub.1026180202"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2022-08-04T16:52", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-springernature-scigraph/baseset/20220804/entities/gbq_results/article/article_299.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "https://doi.org/10.1038/387188a0"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/387188a0'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/387188a0'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/387188a0'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/387188a0'


     

    This table displays all metadata directly associated to this object as RDF triples.

    290 TRIPLES      21 PREDICATES      119 URIs      105 LITERALS      30 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.1038/387188a0 schema:about N03086c299d66408991618bd8537e0301
    2 N06ce4f5bf5434247b28734ecea4a4776
    3 N085e625a0f9c4abc83f309e05f4c8771
    4 N0e5abc282c3f400babce8bc73c084e3a
    5 N1650b5eb9ad240aca27f7e975a0aa3ca
    6 N28402e0bc3a746b09f4870ccdb1fb91a
    7 N2b508c03025c40fe9f1de7d53ecc7c33
    8 N37b6caa63e7349d3a046c90499bcc500
    9 N7cabbd1b29a14eacb801e85d28ef353c
    10 N7d96eb43aae1428eafeff9ad41f41cb0
    11 N856b836521124116a06b1785eebfcf2a
    12 N88b5ffd2d9fd4395b73c841f82123c10
    13 N8edfebf91c924fbdae46b1cbd4dbdc52
    14 N933f70e3bee94dcaaba6fa28fed03477
    15 Nb15f7998af2e47569edb78d27ba644d2
    16 Nc2451b30290d4994b976a9d7a9eac571
    17 Nc62492c223d5480bbe828db3cda076ba
    18 Nc6424d36b3f04651923da9e9420b33da
    19 Nd243deafe1434f2d82bc746192790f44
    20 Nd8d2f055349f48a19c013e9074e693eb
    21 Neffdde9d0c28476397387342e9482e7e
    22 Nf1938101d5664ee99c5f7ac18d549916
    23 Nf24bccc45e6a4993abe86f378f525d7c
    24 anzsrc-for:11
    25 anzsrc-for:1108
    26 schema:author Nce5728a15d104a198aa4143a4c6169c9
    27 schema:citation sg:pub.10.1007/bf01468720
    28 sg:pub.10.1038/360264a0
    29 sg:pub.10.1038/373123a0
    30 sg:pub.10.1038/377740a0
    31 sg:pub.10.1038/387183a0
    32 sg:pub.10.1038/nm1295-1284
    33 schema:datePublished 1997-05
    34 schema:datePublishedReg 1997-05-01
    35 schema:description Analysis of changes in viral load after initiation of treatment with potent antiretroviral agents has provided substantial insight into the dynamics of human immunodeficiency virus type 1 (HIV-1)1–3. The concentration of HIV-1 in plasma drops by ∼99% in the first two weeks of treatment owing to the rapid elimination of free virus with a half-life (t1/2) of ≤6 hours and loss of productively infected cells with a t1/2 of 1.6 days3. Here we show that with combination therapy this initial decrease is followed by a slower second-phase decay of plasma viraemia. Detailed mathematical analysis shows that the loss of long-lived infected cells (t1/2of1–4weeks) is a major contributor to the second phase, whereas the activation of latently infected lymphocytes (t1/2 of 0.5–2 weeks) is only a minor source. Based on these decay characteristics, we estimate that 2.3–3.1 years of a completely inhibitory treatment would be required to eliminate HIV-1 from these compartments. To eradicate HIV-1 completely, even longer treatment may be needed because of the possible existence of undetected viral compartments or sanctuary sites.
    36 schema:genre article
    37 schema:isAccessibleForFree false
    38 schema:isPartOf N545d0d3301ee42b185b31d7ffb8d08cc
    39 N9d44e4b16490483b8b295eaddb81ba96
    40 sg:journal.1018957
    41 schema:keywords HIV
    42 HIV-1
    43 activation
    44 agents
    45 analysis
    46 analysis of changes
    47 antiretroviral agents
    48 cells
    49 changes
    50 characteristics
    51 combination therapy
    52 compartments
    53 concentration
    54 contributor
    55 days3
    56 decay
    57 decay characteristics
    58 decrease
    59 detailed mathematical analysis
    60 drop
    61 dynamics
    62 elimination
    63 existence
    64 free virus
    65 hours
    66 human immunodeficiency virus type 1
    67 immunodeficiency virus type 1
    68 infected cells
    69 inhibitory treatment
    70 initial decrease
    71 initiation
    72 initiation of treatment
    73 insights
    74 load
    75 longer treatment
    76 loss
    77 lymphocytes
    78 major contributor
    79 mathematical analysis
    80 minor source
    81 phase
    82 plasma drop
    83 plasma viraemia
    84 possible existence
    85 potent antiretroviral agents
    86 rapid elimination
    87 sanctuary site
    88 second phase
    89 second-phase decay
    90 sites
    91 source
    92 substantial insight
    93 t1/2
    94 therapy
    95 treatment
    96 type 1
    97 viraemia
    98 viral compartments
    99 viral load
    100 virus
    101 virus type 1
    102 weeks
    103 weeks of treatment
    104 years
    105 schema:name Decay characteristics of HIV-1-infected compartments during combination therapy
    106 schema:pagination 188-191
    107 schema:productId N535a7706edcd4fe1b5bfb542905069d2
    108 N6385c515005647338533ee77875533cb
    109 N64a2b454c6354b33a533a1d5d39c980f
    110 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026180202
    111 https://doi.org/10.1038/387188a0
    112 schema:sdDatePublished 2022-08-04T16:52
    113 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    114 schema:sdPublisher Nd56bfcc4328c4a44b597323eb3b93e52
    115 schema:url https://doi.org/10.1038/387188a0
    116 sgo:license sg:explorer/license/
    117 sgo:sdDataset articles
    118 rdf:type schema:ScholarlyArticle
    119 N03086c299d66408991618bd8537e0301 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    120 schema:name Macrophages
    121 rdf:type schema:DefinedTerm
    122 N06ce4f5bf5434247b28734ecea4a4776 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    123 schema:name CD4-Positive T-Lymphocytes
    124 rdf:type schema:DefinedTerm
    125 N085e625a0f9c4abc83f309e05f4c8771 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    126 schema:name Leukocytes, Mononuclear
    127 rdf:type schema:DefinedTerm
    128 N0e5abc282c3f400babce8bc73c084e3a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    129 schema:name Drug Therapy, Combination
    130 rdf:type schema:DefinedTerm
    131 N1650b5eb9ad240aca27f7e975a0aa3ca schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    132 schema:name Mathematics
    133 rdf:type schema:DefinedTerm
    134 N28402e0bc3a746b09f4870ccdb1fb91a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    135 schema:name Virus Latency
    136 rdf:type schema:DefinedTerm
    137 N2b508c03025c40fe9f1de7d53ecc7c33 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    138 schema:name RNA, Viral
    139 rdf:type schema:DefinedTerm
    140 N37b6caa63e7349d3a046c90499bcc500 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    141 schema:name Sulfonic Acids
    142 rdf:type schema:DefinedTerm
    143 N535a7706edcd4fe1b5bfb542905069d2 schema:name pubmed_id
    144 schema:value 9144290
    145 rdf:type schema:PropertyValue
    146 N545d0d3301ee42b185b31d7ffb8d08cc schema:issueNumber 6629
    147 rdf:type schema:PublicationIssue
    148 N558c79a439ea4c20ac3805cdf774b546 rdf:first sg:person.01342367032.44
    149 rdf:rest N60b33f605ba244f691a6dd15a14b044a
    150 N60b33f605ba244f691a6dd15a14b044a rdf:first sg:person.01343017451.31
    151 rdf:rest N9547d14e89f34e50afd166b87f0a5a43
    152 N6333fcb6b0d04788bb412aff8bb0b868 rdf:first sg:person.01342202624.34
    153 rdf:rest rdf:nil
    154 N6385c515005647338533ee77875533cb schema:name dimensions_id
    155 schema:value pub.1026180202
    156 rdf:type schema:PropertyValue
    157 N64a2b454c6354b33a533a1d5d39c980f schema:name doi
    158 schema:value 10.1038/387188a0
    159 rdf:type schema:PropertyValue
    160 N7cabbd1b29a14eacb801e85d28ef353c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    161 schema:name Reverse Transcriptase Inhibitors
    162 rdf:type schema:DefinedTerm
    163 N7d96eb43aae1428eafeff9ad41f41cb0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    164 schema:name Anti-HIV Agents
    165 rdf:type schema:DefinedTerm
    166 N856b836521124116a06b1785eebfcf2a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    167 schema:name Humans
    168 rdf:type schema:DefinedTerm
    169 N88b5ffd2d9fd4395b73c841f82123c10 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    170 schema:name Nelfinavir
    171 rdf:type schema:DefinedTerm
    172 N8edfebf91c924fbdae46b1cbd4dbdc52 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    173 schema:name Viremia
    174 rdf:type schema:DefinedTerm
    175 N933f70e3bee94dcaaba6fa28fed03477 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    176 schema:name HIV Protease Inhibitors
    177 rdf:type schema:DefinedTerm
    178 N9547d14e89f34e50afd166b87f0a5a43 rdf:first sg:person.01370270152.62
    179 rdf:rest Nbc03eafed226474da14a5bd8a2885c25
    180 N98cbf3afdb574f3189d772284d2d612f rdf:first sg:person.016673513377.34
    181 rdf:rest N6333fcb6b0d04788bb412aff8bb0b868
    182 N9d44e4b16490483b8b295eaddb81ba96 schema:volumeNumber 387
    183 rdf:type schema:PublicationVolume
    184 Nb15f7998af2e47569edb78d27ba644d2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    185 schema:name Half-Life
    186 rdf:type schema:DefinedTerm
    187 Nbc03eafed226474da14a5bd8a2885c25 rdf:first sg:person.01154520206.45
    188 rdf:rest Nebc8a68039c0475ab7006887d91b257d
    189 Nc2451b30290d4994b976a9d7a9eac571 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    190 schema:name HIV-1
    191 rdf:type schema:DefinedTerm
    192 Nc62492c223d5480bbe828db3cda076ba schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    193 schema:name Lamivudine
    194 rdf:type schema:DefinedTerm
    195 Nc6424d36b3f04651923da9e9420b33da schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    196 schema:name Viral Load
    197 rdf:type schema:DefinedTerm
    198 Nce5728a15d104a198aa4143a4c6169c9 rdf:first sg:person.01335541022.50
    199 rdf:rest N558c79a439ea4c20ac3805cdf774b546
    200 Nd243deafe1434f2d82bc746192790f44 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    201 schema:name Zidovudine
    202 rdf:type schema:DefinedTerm
    203 Nd56bfcc4328c4a44b597323eb3b93e52 schema:name Springer Nature - SN SciGraph project
    204 rdf:type schema:Organization
    205 Nd8d2f055349f48a19c013e9074e693eb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    206 schema:name HIV Infections
    207 rdf:type schema:DefinedTerm
    208 Nebc8a68039c0475ab7006887d91b257d rdf:first sg:person.01172560566.03
    209 rdf:rest N98cbf3afdb574f3189d772284d2d612f
    210 Neffdde9d0c28476397387342e9482e7e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    211 schema:name Proviruses
    212 rdf:type schema:DefinedTerm
    213 Nf1938101d5664ee99c5f7ac18d549916 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    214 schema:name Isoquinolines
    215 rdf:type schema:DefinedTerm
    216 Nf24bccc45e6a4993abe86f378f525d7c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    217 schema:name Models, Biological
    218 rdf:type schema:DefinedTerm
    219 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
    220 schema:name Medical and Health Sciences
    221 rdf:type schema:DefinedTerm
    222 anzsrc-for:1108 schema:inDefinedTermSet anzsrc-for:
    223 schema:name Medical Microbiology
    224 rdf:type schema:DefinedTerm
    225 sg:journal.1018957 schema:issn 0028-0836
    226 1476-4687
    227 schema:name Nature
    228 schema:publisher Springer Nature
    229 rdf:type schema:Periodical
    230 sg:person.01154520206.45 schema:affiliation grid-institutes:grid.148313.c
    231 schema:familyName Hurley
    232 schema:givenName Arlene
    233 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01154520206.45
    234 rdf:type schema:Person
    235 sg:person.01172560566.03 schema:affiliation grid-institutes:grid.148313.c
    236 schema:familyName Saksela
    237 schema:givenName Kalle
    238 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01172560566.03
    239 rdf:type schema:Person
    240 sg:person.01335541022.50 schema:affiliation grid-institutes:grid.148313.c
    241 schema:familyName Perelson
    242 schema:givenName Alan S.
    243 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01335541022.50
    244 rdf:type schema:Person
    245 sg:person.01342202624.34 schema:affiliation grid-institutes:grid.148313.c
    246 schema:familyName Ho
    247 schema:givenName David D.
    248 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01342202624.34
    249 rdf:type schema:Person
    250 sg:person.01342367032.44 schema:affiliation grid-institutes:grid.148313.c
    251 schema:familyName Essunger
    252 schema:givenName Paulina
    253 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01342367032.44
    254 rdf:type schema:Person
    255 sg:person.01343017451.31 schema:affiliation grid-institutes:grid.148313.c
    256 schema:familyName Cao
    257 schema:givenName Yunzhen
    258 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01343017451.31
    259 rdf:type schema:Person
    260 sg:person.01370270152.62 schema:affiliation grid-institutes:grid.148313.c
    261 schema:familyName Vesanen
    262 schema:givenName Mika
    263 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01370270152.62
    264 rdf:type schema:Person
    265 sg:person.016673513377.34 schema:affiliation grid-institutes:grid.148313.c
    266 schema:familyName Markowitz
    267 schema:givenName Martin
    268 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016673513377.34
    269 rdf:type schema:Person
    270 sg:pub.10.1007/bf01468720 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005527589
    271 https://doi.org/10.1007/bf01468720
    272 rdf:type schema:CreativeWork
    273 sg:pub.10.1038/360264a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017658165
    274 https://doi.org/10.1038/360264a0
    275 rdf:type schema:CreativeWork
    276 sg:pub.10.1038/373123a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014949926
    277 https://doi.org/10.1038/373123a0
    278 rdf:type schema:CreativeWork
    279 sg:pub.10.1038/377740a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020157720
    280 https://doi.org/10.1038/377740a0
    281 rdf:type schema:CreativeWork
    282 sg:pub.10.1038/387183a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036513917
    283 https://doi.org/10.1038/387183a0
    284 rdf:type schema:CreativeWork
    285 sg:pub.10.1038/nm1295-1284 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020288435
    286 https://doi.org/10.1038/nm1295-1284
    287 rdf:type schema:CreativeWork
    288 grid-institutes:grid.148313.c schema:alternateName Theoretical Division, Los Alamos National Laboratory, 87545, Los Alamos, New Mexico, USA
    289 schema:name Theoretical Division, Los Alamos National Laboratory, 87545, Los Alamos, New Mexico, USA
    290 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...